WASHINGTON, D.C. -- Following reports that congressional leadership is pushing to include language in the third phase of coronavirus legislation to artificially fix prices in an effort to address medical “surprise billing,” Jason Pye, FreedomWorks’ Vice President of Legislative Affairs, commented:

WASHINGTON, D.C. -- In response to the Trump Administration’s announcements of CMS loosening regulations for telehealth in Medicare and FDA empowering states on testing in efforts to counter the COVID-19 pandemic, Adam Brandon, FreedomWorks’ President, commented:

WASHINGTON, D.C. -- In response to the insertion of a provision calling for price controls on vaccines in the congressional coronavirus package, Adam Brandon, FreedomWorks’ President, commented:

WASHINGTON, D.C. -- In response to efforts by Democratic House leadership to tie the reauthorization of the USA PATRIOT Act to the coronavirus spending package, Jason Pye, FreedomWorks’ Vice President of Legislative Affairs, commented:

WASHINGTON, D.C. -- In response to Sen. Chuck Grassley’s (R-Iowa) most recent support for government mandated price controls on prescription drugs, Dan Savickas, FreedomWorks Regulatory Policy Manager, commented:

WASHINGTON, D.C. -- In response to the closing of the comment period on the Center for Medicare and Medicaid Services’ proposal on organ procurement, Dan Savickas, FreedomWorks Foundation Regulatory Policy Manager, commented:

WASHINGTON, D.C. -- In response to the Trump Administration’s recent decision to proceed with a rules change that will initiate much needed organ procurement organization (OPO) reform, Adam Brandon, FreedomWorks’ president, commented: